|Li Gao, M.Sc
(M.Sc: Trauner group, LMU; Work Internship: Bayer)
Li was the first to join the Group, in 2017.01. With a background in organic synthesis, he now works on the synthesis of topoisomerase-targeted pharmacogenic prodrugs and photoswitchable inhibitors, as well as semisynthesis of natural product photoswitches.
firstname.lastname@example.org; C1.011; +49 89 2180-77926
|Adrian Müller-Deku, M.Sc
(M.Sc: Didier group, LMU; Work Internships: Solvay and Bayer)
Adrian joined the Group in 2017.10 and has a background in organic and inorganic synthesis. His projects focus on the synthesis of tubulin-targeted photoswitchable inhibitors and chemical biology reagents.
email@example.com; C01.011; +49 89 2180-77232
|Yvonne Kraus, M.Sc
(M.Sc: Gerisch group, MPI; Work Internships: BCA Augsburg and MPI)
Yvonne joined the group in 2017.05 then started her PhD in 2018.01. She is evaluating photoswitchable reagents for subcellular control over the tubulin cytoskeleton.
firstname.lastname@example.org; C0.065; +49 89 2180-77227
|Alexander Sailer, M.Sc
(M.Sc: Holzgrabe group, Würzburg / Szklarzewicz group, Cracow)
Alexander started with us in 2018.06, working on the synthesis of diverse families of photoswitches to modulate cell survival and biophysical properties, and with a strong sideline in fluorescence.
email@example.com; C1.011; +49 89 2180-77926
|Jan Felber, M.Sc
(M.Sc: Thorn-Seshold Group, LMU Munich; Work Internship: Bayer)
Jan joined the Group in 2018.01 for a Masters and will start his PhD in 2018.11. Jan's background is in organic synthesis which he has balanced with in vitro biology, focussing on the synthesis and applications of probes for redox biology.
firstname.lastname@example.org; C1.009; +49 89 2180-77925
|Franziska Ermer, Vet. StEx
Franziska is a veterinarian who joined the Group in 2018.09. She works on testing our compounds for anticancer activity in vivo in mouse models and has a particular focus on angiogenesis and vascular disruption.
email@example.com; K0.036: -71035 / C0.065: -77224
|Dr. Kristina Loy
(PhD: Bareyre, LMU Biomedical Centre)
Kristina joins us the group from 2019.04 as a cell & molecular biology postdoc, working on biological evaluations of redox prodrugs and tubulin reagents.
firstname.lastname@example.org; K0.036; +49 89 2180-71035
|Dr. Marcel Klingenberg
(PhD: Diederichs, DKFZ Heidelberg)
Marcel joins the Group from 2019.04 as a cell & molecular biology postdoc, working on biological evaluations of anti-angiogenic agents and topoisomerase inhibitors.
email@example.com; K0.036; +49 89 2180-71035
|Ruchira Shah, M.Sc.
(JRF: Jayakannan lab, IISER Pune; SRF: Pawar lab, Pune)
Ruchira joins us from the University of Pune as a CeNS Scholar from 2018.10-2019.04, working on biological evaluations of our topoisomerase inhibitors.
C0.065; Phone: +49 89 2180-77224
|Katarzyna "Kasia" Pańczyk, M.Sc.
(PhD: Waszkielewicz lab, Jagiellonian University Kraków)
Katarzyna joins the Group from 2018.12-2019.05 as a DAAD Visiting Scholar, to synthesise photoswitchable modulators of TRPM function.
firstname.lastname@example.org; C1.009; +49 89 2180-77925
Sonja joined the Group in 2018.11 with a background in synthetic chemistry. Her Masters project focusses on the synthesis of novel topoisomerase inhibitors.
email@example.com; C1.009; +49 89 2180-77925
Bekkah did her BSc with us in 2017, and came back for internships in 2017 and 2018, on synthesis and characterisation of MRI-active and fluorescent nanoparticles. After an exchange to Umea University, in Feb 2019 she returns for a Masters working on tubulin biochemistry.
firstname.lastname@example.org; C1.011;+49 89 2180-77232
|Dr. Yelena Wainman (PhD: Leeper/Brindle, Cambridge; Postdoc: Mazitschek, Harvard) joined the Group in 2016.09, with a background in chemical biology, and co-leads the CytoSwitch translational project. Dr. Elena Longhi (PhD: Licandro, Uni. Milan; Postdocs: de Cola, Uni. Strasbourg; Marder, Georgia Tech) joined in 2018.10 as a synthetic chemist with experience in photoactives, and heads compound creation in the project. Tilmann Petersen (VivoCell, Pioneers.io) joined in 2018.03, with a background in biotech and tech entrepreneurship, to ensure the project's translational progress. Dr. Wen-Hsin Liu (PhD: Sun Yat-Sen University; Postdoc: Jeremias, Helmholtz; Fässler, MPI) joined in 2019.03 and with her experience in in vivo biology is responsible for the project's in vivo science.
Rooms: K0.032/036; Phone: +49 89 2180-71034/71035 (EL: Room: C1.009; Phone: 77925).
email@example.com; firstname.lastname@example.org; email@example.com; firstname.lastname@example.org
|Dr. Petar Marinković (PhD: Misgeld, TUM; Postdoc: Herms, DZNE) joined the Group in 2017.04 with a background in in vivo imaging and neuroscience, and co-leads the NanoCapture translational project. Dr. Julia Ahlfeld (PhD: Schüller, LMU Hospital; Postdoc: Rothenfusser, LMU Hospital) joined the Group in 2018.07 with experience in in vivo disease models and in clinical trials, and is responsible for the project's in vivo science. Constanze Heise (Prev: Immunopharmacology, LMU University Hospital) joins the Group in 2018.04 as a highly experienced BTA running in vivo assays in the project. Monique Preuße (Prev: Immunopharmacology, LMU University Hospital) also joins the Group in 2018.04 as BTA for in vitro and in vivo work in the project.
Rooms: K0.032/36 (BioSysM); Phone: +49 89 2180-71034/71035 (CH/MP: C0.057, -77224).
email@example.com; firstname.lastname@example.org; email@example.com; firstname.lastname@example.org
Fabian joins Alex for an F-Praktikum synthesising cruel and unusual tubulin inhibitors. Stay tuned!
Room: C1.011; Phone: +49 89 2180-77926